NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis
Advanced SearchBrowse by AnalyteBrowse by Pre-analytical FactorSearch SOPsSOP Compendiums

Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues.

Author(s): Berg D, Langer R, Tran K, Walch A, Schuster T, Bronger H, Becker KF

Publication: Appl Immunohistochem Mol Morphol, 2011, Vol. 19, Page 300-5

PubMed ID: 21293257 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to compare expression levels of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) by reverse phase protein microarray (RPPA) using protein extracted from archival formalin-fixed paraffin-embedded (FFPE) surgical excision specimens as well as core biopsy specimens.

Conclusion of Paper

Protein expression values for ER, PR, and HER2 were highly concordant between core biopsies and surgical excision specimens when expression was assessed by RPPA. In addition, RPPA results were highly concordant with immunohistochemistry (IHC) results for both types of specimens.

Studies

  1. Study Purpose

    The purpose of this study was to compare HER2, ER, and PR protein expression in core biopsies and surgical excision specimens using RPPA. Additionally, RPPA results were compared with IHC results. FISH was used to further evaluate HER2 status of specimens scored as 2+ by IHC.

    Summary of Findings:

    Absolute concordance rates between surgical specimens and core biopsies were 91.4% for HER2, 80% for ER, and 82.8% for PR. For HER2, 1/35 specimens was classified as HER2+ in the surgical specimen but HER2- in the core biopsy, while 2/35 specimens were HER2- in the surgical specimen but HER2+ in the core biopsy. For ER, 1/35 specimens was classified as ER+ in the surgical specimen but ER- in the core biopsy, while 6/35 specimens were ER- in the surgical specimen but ER+ in the core biopsy. For PR, 4/35 specimens were classified as PR+ in the surgical specimen but PR- in the core biopsy, while 2/35 specimens were PR- in the surgical specimen but PR+ in the core biopsy. Concordance rates of 100% and 94.2% were seen between RPPA and IHC for surgical specimens and core biopsies, respectively.

    Biospecimens
    Preservative Types
    • Formalin
    Diagnoses:
    • Neoplastic - Carcinoma
    Platform:
    AnalyteTechnology Platform
    Protein Reverse phase protein microarray
    Protein Immunohistochemistry
    DNA FISH
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Immunohistochemistry Specific Targeted peptide/protein HER2
    ER
    PR
    FISH Specific Targeted nucleic acid HER2
    Reverse phase protein microarray Specific Technology platform Immunohistochemistry
    Reverse phase protein microarray Specific Targeted peptide/protein HER2
    ER
    PR
    Biospecimen Acquisition Method of tissue acquisition Core needle biopsy
    Surgical resection
    View more

You Recently Viewed  

News and Announcements

  • April 24, 2024: Biobanking for Precision Medicine Seminar
  • Most Popular SOPs in March 2024
  • New SOPs Available
    • More...